Zobrazeno 1 - 10
of 61
pro vyhledávání: '"A. Yubero Esteban"'
Autor:
Fernandez-Serra, Antonio, López-Reig, Raquel, Márquez, Raúl, Gallego, Alejandro, De Sande-González, Luis Miguel, Yubero Esteban, Alfonso, OAKNIN, ANA
Publikováno v:
Scientia
Genomic instability; Machine learning Inestabilidad genómica; Aprendizaje automático Inestabilitat genòmica; Aprenentatge automàtic Genomic Instability (GI) is a transversal phenomenon shared by several tumor types that provide both prognostic an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3991::94cd02cc9b31e807ec9ecb23f6ca0321
https://hdl.handle.net/11351/9746
https://hdl.handle.net/11351/9746
Autor:
Andrew Weaver, Steve Bandula, Ewan Brown, Alfonso Yubero Esteban, Philip Sinclair, Armeen Mahvash, Mary F. Mulcahy, Etienne Garin, Constantinos T. Sofocleous, William P. Harris, Paul Ross, Robert C.G. Martin, Amir H Montazeri, Siddharth A. Padia, Marc Pracht, Darryl Zuckerman, Ken Herrmann, Matthew S. Johnson, Gregory C. Wilson, Janet Graham, Riad Salem, Tae-You Kim, Robert J. Lewandowski, Jamie Mills
Publikováno v:
Journal of Clinical Oncology. 39:3897-3907
PURPOSE To study the impact of transarterial Yttrium-90 radioembolization (TARE) in combination with second-line systemic chemotherapy for colorectal liver metastases (CLM). METHODS In this international, multicenter, open-label phase III trial, pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6d03f73b0333d6da7b782768ee70fe2
https://doi.org/10.1200/jco.21.01839
https://doi.org/10.1200/jco.21.01839
Autor:
M. Zapata García, R. Lastra, A. Moratiel Pellitero, M. Gascon Ruiz, A. Sesma Goñi, E. Quilez Bielsa, M. Cruellas Lapena, J.R. Paño-Pardo, R. Del Campo, M.I. Torres Ramon, A. Yubero Esteban, A. Ramírez-Labrada, E.M. Gálvez, J. Pardo, M.D. Isla Casado
Publikováno v:
Journal of Thoracic Oncology. 18:S140-S141
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::731b2d1d9442a1e82859ad2b41bc39e4
https://doi.org/10.1016/s1556-0864(23)00438-0
https://doi.org/10.1016/s1556-0864(23)00438-0
Autor:
A. Goel, C. Xu, S. Roy, F.M. Esposito, O. Helena, V. Alonso, A. Yubero Esteban, F-M. Carlos, M.A. Salud Salvia, J. Gallego Plazas, J.R. Rodriguez Monwbray, M.M-R. Marta, J. Fernandez, H. Manzano, J. Aparicio, J. Feliu, J. Maurel
Publikováno v:
Annals of Oncology. 33:S711-S712
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4da9704a7c5cdc0089d9673b85c06ee3
https://doi.org/10.1016/j.annonc.2022.07.521
https://doi.org/10.1016/j.annonc.2022.07.521
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
P Reche, G Marquina, Lizet Sánchez, B Pajares Hachero, C Salvador, J Calzas, M Merino, L Gaba, Á Taus, J.D. Alarcon, Raul Marquez, J Madani, A Yubero-Esteban, A Herrero-Ibáñez, Ana Santaballa, P Estévez, Luis Manso, J Fuentes-Pradera, Antonio González-Martín, A Barquin
Publikováno v:
Ovarian cancer.
Introduction/Background* Rucaparib is a PARP-1/2/3 inhibitor approved for the treatment of high-grade ovarian cancer (HGOC). In ARIEL3, rucaparib improved PFS as maintenance therapy for platinum (Pt)-sensitive recurrent OC. Study 10, ARIEL2, and ARIE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::993791e855a3f583fe37abee6296ed72
https://doi.org/10.1136/ijgc-2021-esgo.398
https://doi.org/10.1136/ijgc-2021-esgo.398
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Alfonso Yubero-Esteban, Piedad Reche-Molina, Carmen Salvador Coloma, Purificación Estévez-García, Luis Manso, Marcos Iglesias Campos, Arantzazu Barquin, Raul Marquez, Ana Santaballa, Julia Calzas, Ana Herrero, Victoria Casado, Julia Madani, Maria Merino, Gloria Marquina, Jesus Alarcon Company, Lydia Gaba, Jose Fuentes Pradera, Antonio Gonzalez Martin, Maria Luisa Sanchez Lorenzo
Publikováno v:
Journal of Clinical Oncology. 40:e17598-e17598
e17598 Background: Rucaparib is a PARP inhibitor (PARPi) approved as maintenance therapy for platinum (Pt)-sensitive recurrent high-grade ovarian cancer (HGOC), and as treatment for BRCA-mutant HGOC patients. To date, there is little evidence about t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35357b7514f82b11ae213ede72dccbfa
https://doi.org/10.1200/jco.2022.40.16_suppl.e17598
https://doi.org/10.1200/jco.2022.40.16_suppl.e17598
Autor:
Alfonso Yubero-Esteban, Arantzazu Barquin, Lydia Gaba, Marcos Iglesias Campos, Piedad Reche-Molina, Carmen Salvador Coloma, Jesus Alarcon Company, Luis Manso, Raul Marquez, Jose Fuentes Pradera, Julia Madani, Manuel Constenla Figueiras, Maria Gutierrez-Toribio, Purificación Estévez-García, Ana Santaballa, Maria Luisa Sanchez Lorenzo, Julia Calzas, Ana Herrero, Alvaro Taus, Antonio Gonzalez Martin
Publikováno v:
Journal of Clinical Oncology. 40:e17562-e17562
e17562 Background: Rucaparib is a PARP inhibitor approved for the treatment of high-grade ovarian cancer (HGOC). Clinical trials have demonstrated its benefit both as maintenance therapy (MTN) for platinum (Pt)-sensitive recurrent HGOC, and as treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c1d2e535fcfd2ecf856d876c38e5087
https://doi.org/10.1200/jco.2022.40.16_suppl.e17562
https://doi.org/10.1200/jco.2022.40.16_suppl.e17562
Autor:
G. Villacampa Javierre, Lorena Fariñas-Madrid, A. Yubero Esteban, A. Gallego Martínez, J.M. Piulats, F. Grau, B. Pardo Burdalo, M.L. Sanchez Lorenzo, Fiorella Ruiz-Pace, Andrés Redondo, Mauricio Rubio, M. Gil-Martin, Jesús García-Donas, Ignacio A. Romero, Antonio González-Martín, Ana Oaknin
Publikováno v:
Annals of Oncology. 32:S761-S762
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7e45d4517e99d2c6fe85a4f02f113ec
https://doi.org/10.1016/j.annonc.2021.08.1240
https://doi.org/10.1016/j.annonc.2021.08.1240